Evidence map›Paper›PMID 25404125›Full record

ArticleThe New England journal of medicine2014

HDL cholesterol efflux capacity and incident cardiovascular events.

Anand Rohatgi, Amit Khera, Jarett D Berry, Edward G Givens, Colby R Ayers, Kyle E Wedin, Ian J Neeland, Ivan S Yuhanna, Daniel R Rader, James A de Lemos and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in The New England journal of medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 726 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
726citing papers in PubMed, 5 pooled it
124.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

726 citing papers in PubMed, 5 syntheses or guidelines pooled it, 1,369 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Impact of a Chokeberry (Nutrients · 2025
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Observational
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Early atherogenesis: In search of etiology.International journal of cardiology. Cardiovascular risk and prevention · 2026
    Review
  20. Article

666 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Anand RohatgiFrom the Division of Cardiology, Department of Internal Medicine (A.R., A.K., J.D.B., E.G.G., C.R.A., I.J.N., J.A.L.), and the Center for Pulmonary and Vascular Biology, Department of Pediatrics (I.S.Y., P.W.S.), University of Texas Southwestern Medical Center, Dallas; the Department of Internal Medicine, Emory University, Atlanta (K.E.W.); and the Departments of Genetics and Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia (D.R.R.).
Amit Khera
Jarett D Berry
Edward G Givens
Colby R Ayers
Kyle E Wedin
Ian J Neeland
Ivan S Yuhanna
Daniel R Rader
James A de Lemos
Philip W Shaul
The University of Texas Southwestern Medical Center · USEmory University · USUniversity of Pennsylvania · US

Funding

UT Southwestern Center for Translational Medicine (UL1/KL2/TL1)UL1TR001105 · NCATS · UT SOUTHWESTERN MEDICAL CENTER · PI TOTO, ROBERT DANIEL · 2013 to 2017
$24.5M
Moving Beyond HDL Cholesterol, HDL Function as a Coronary Disease BiomarkerK08HL118131 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI ROHATGI, ANAND KUMAR · 2013 to 2017
$665k
NCATS NIH HHS UL1 TR001105NCATS NIH HHS UL1TR001105NHLBI NIH HHS K08 HL118131NHLBI NIH HHS K08HL1813
6 · The paper itself

Abstract

backgroundIt is unclear whether high-density lipoprotein (HDL) cholesterol concentration plays a causal role in atherosclerosis. A more important factor may be HDL cholesterol efflux capacity, the ability of HDL to accept cholesterol from macrophages, which is a key step in reverse cholesterol transport. We investigated the epidemiology of cholesterol efflux capacity and its association with incident atherosclerotic cardiovascular disease outcomes in a large, multiethnic population cohort.

methodsWe measured HDL cholesterol level, HDL particle concentration, and cholesterol efflux capacity at baseline in 2924 adults free from cardiovascular disease who were participants in the Dallas Heart Study, a probability-based population sample. The primary end point was atherosclerotic cardiovascular disease, defined as a first nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization or death from cardiovascular causes. The median follow-up period was 9.4 years.

resultsIn contrast to HDL cholesterol level, which was associated with multiple traditional risk factors and metabolic variables, cholesterol efflux capacity had minimal association with these factors. Baseline HDL cholesterol level was not associated with cardiovascular events in an adjusted analysis (hazard ratio, 1.08; 95% confidence interval [CI], 0.59 to 1.99). In a fully adjusted model that included traditional risk factors, HDL cholesterol level, and HDL particle concentration, there was a 67% reduction in cardiovascular risk in the highest quartile of cholesterol efflux capacity versus the lowest quartile (hazard ratio, 0.33; 95% CI, 0.19 to 0.55). Adding cholesterol efflux capacity to traditional risk factors was associated with improvement in discrimination and reclassification indexes.

conclusionsCholesterol efflux capacity, a new biomarker that characterizes a key step in reverse cholesterol transport, was inversely associated with the incidence of cardiovascular events in a population-based cohort. (Funded by the Donald W. Reynolds Foundation and others.).

Indexed as

AdultAtherosclerosisBiological TransportBiomarkersCardiovascular DiseasesCholesterol, LDLFemaleFollow-Up StudiesHumansIncidenceLipoproteins, HDLMaleMiddle AgedRisk FactorsBiomarkersCholesterol, LDLLipoproteins, HDL

Identifiers

PMID25404125
PMCPMC4308988
OpenAlexW2109429564

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.